logo
  

Moderna's Omicron-targeting Booster Covid-19 Vaccine Gets Clearance In Switzerland

Moderna, Inc. (MRNA) said on Monday that it has received a temporary authorization in Switzerland for its Omicron-targeting bivalent booster vaccine, Spikevax Bivalent Original/Omicron or mRNA-1273.214, to prevent Covid-19 among the people above 18 years.

Spikevax Bivalent Original/Omicron is a bivalent vaccine that contains 25 µg of mRNA-1273 (Spikevax), and 25 µg of a vaccine candidate targeting the Omicron variant of concern (BA.1).

Study results showed that mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273.

Moderna aims to make Spikevax Bivalent Original/Omicron available to the Swiss people in early September.

The drug major has already received approval for mRNA-1273.214 in the UK, and has also completed regulatory submissions for the next-generation vaccine worldwide.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. plans to start using American-made processors from the new advanced chip factory in Phoenix, Arizona operated by chip giant Taiwan Semiconductor Manufacturing Co., according to its Chief Executive Officer Tim Cook. At an event in the factory in Arizona, which was attended by U.S. President Joe Biden, it was also announced that TSMC will invest $40 billion in the new factory. Lidl US has recalled its 8.4 oz Favorina branded Advent Calendar, i.e., Premium Chocolate with a Creamy Filling, citing potential Salmonella contamination, the U.S. Food and Drug Administration said. The products were available for sale at Lidl stores between October 12, 2022 and December 5, 2022. They will have a BEST IF USED BY year of 2023, and barcode number of 4056489516965. Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group.
Follow RTT